Education
- PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
Research Summary
We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.Awards
- Forbeck Fellow, 2015
Recent Publications
- Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Mahat, DB, Kumra, H, Castro, SA, Metcalf, E, Nguyen, K, Morisue, R, Ho, WW, Chen, I, Sullivan, B, Yim, LH et al.. 2025. Immunity 58, 1688-1705.e9.
doi: 10.1016/j.immuni.2025.06.005PMID:40592342 - Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer. Bhandarkar, V, Dinter, T, Spranger, S. 2025. Sci Immunol 10, eadf4726.
doi: 10.1126/sciimmunol.adf4726PMID:39823318 - Cancer immune evasion, immunoediting and intratumour heterogeneity. Roerden, M, Spranger, S. 2025. Nat Rev Immunol 25, 353-369.
doi: 10.1038/s41577-024-01111-8PMID:39748116 - Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion. Torres-Mejia, E, Weng, S, Whittaker, CA, Nguyen, KB, Duong, E, Yim, L, Spranger, S. 2025. Cancer Immunol Res 13, 496-516.
doi: 10.1158/2326-6066.CIR-24-0184PMID:39745382 - Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. Roerden, M, Castro, AB, Cui, Y, Harake, N, Kim, B, Dye, J, Maiorino, L, White, FM, Irvine, DJ, Litchfield, K et al.. 2024. J Immunother Cancer 12, .
doi: 10.1136/jitc-2024-010249PMID:39521615 - Validation and quantification of peptide antigens presented on MHCs using SureQuant. Leddy, O, Cui, Y, Ahn, R, Stopfer, L, Choe, E, Kim, DH, Roerden, M, Spranger, S, Bryson, BD, White, FM et al.. 2025. Nat Protoc 20, 1196-1222.
doi: 10.1038/s41596-024-01076-xPMID:39438697 - Expansion of tumor-reactive CD8+ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Morgan, DM, Horton, BL, Bhandarkar, V, Van, R, Dinter, T, Zagorulya, M, Love, JC, Spranger, S. 2024. Sci Immunol 9, eadi3487.
doi: 10.1126/sciimmunol.adi3487PMID:39270006 - Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer. Mahat, DB, Kumra, H, Castro, SA, Metcalf, E, Nguyen, K, Morisue, R, Ho, WW, Chen, I, Sullivan, B, Yim, LK et al.. 2024. bioRxiv , .
doi: 10.1101/2024.08.28.609802PMID:39257788 - Transforming ovarian cancer care by targeting minimal residual disease. Jazaeri, AA, Grisham, R, Knisely, A, Spranger, S, Zamarin, D, Hillman, RT, Lawson, BC, Burns, KH, Lee, S, Westin, SN et al.. 2023. Med 4, 755-760.
doi: 10.1016/j.medj.2023.08.004PMID:37951209 - Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2. Horton, BL, D'Souza, AD, Zagorulya, M, McCreery, CV, Abhiraman, GC, Picton, L, Sheen, A, Agarwal, Y, Momin, N, Wittrup, KD et al.. 2023. JCI Insight 8, .
doi: 10.1172/jci.insight.172728PMID:37669107
Multimedia